Splet06. sep. 2024 · Sutimlimab(又名TNT003、BIVV-009)是Sanofi旗下子公司Bioverativ开发的一款抗补体C1s的IgG4人源化单克隆抗体药物,主要被开发用于CAD等补体途径介导的疾病治疗。 今年5月,Sanofi宣布FDA已受理sutimlimab治疗原发性冷凝集素病(CAD)成人患者溶血的生物制品许可申请(BLA),并授予了优先审查资格。 临床前 临床前试验中,研 … SpletTelefonischer Kontakt 0800 0752002 Montag bis Freitag 9:00 – 17:00 Uhr Kundenbetreuung für Apotheken, Krankenhäuser und Großhändler 0800 7242410 Meldung von unerwünschten Arzneimittelwirkungen oder Produktbeanstandungen 0800 0752002 Klinische Studien Möchten Sie mehr über unsere klinischen Studien erfahren? Klicken Sie hier
European Medicines Agency
Splet13. jan. 2024 · sutimlimab. Therapeutic area. Haematology-Hemostaseology. Decision number. P/0146/2024. PIP number. EMEA-002542-PIP03-20. Pharmaceutical form (s) All … Splet08. apr. 2024 · Background: Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway. duval sheriff department
如何记住所有FDA批准生物药? 补体C1s抑制剂
SpletINDICATION ENJAYMO ® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD). It is not known if … SpletENJAYMO ® (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). Please see full Prescribing Information. See the full … Splet20. maj 2024 · Sutimlimab is a monoclonal antibody directed towards complement subunit C1s used to reduce the need for blood transfusion due to hemolysis in patients with cold agglutinin disease. Brand Names Enjaymo Generic Name Sutimlimab DrugBank Accession Number DB14996 Background duval showcase